BiotechTube
Home/Denali Therapeutics/Marc Tessier-Lavigne
MT

Marc Tessier-Lavigne

Board Member

Denali Therapeutics

Therapeutic Areas

Neurodegenerative DiseasesLysosomal Storage DisordersCentral Nervous System (CNS)

Denali Therapeutics Pipeline

DrugIndicationPhase
DNL310 (etrasimod)MPS II (Hunter syndrome)Phase 2/3
BIIB122/DNL151Parkinson's diseasePhase 3
DNL919Alzheimer's diseasePhase 1b
SAR443820/DNL788Amyotrophic Lateral Sclerosis (ALS)Phase 2
TV-Enabled Antibody Platform CandidatesNeurodegenerative Diseases (e.g., targeting alpha-synuclein, tau)Preclinical/Discovery

Leadership Team at Denali Therapeutics

RW
Ryan Watts
Chief Executive Officer
AS
Alexander Schuth
Chief Operating Officer
SK
Steve Krognes
Chief Financial Officer
CH
Carole Ho
Chief Medical Officer
TC
Todd Carter
Chief Scientific Officer
AS
Amit Sachdev
Chief Business Officer
View full Denali Therapeutics profile